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Abstract
Dietary supplements have been suggested in the prevention of the common cold, but previous investigations have been inconsistent.
The present study was designed to determine the preventive effect of a dietary supplement from fruits and vegetables on common
cold symptoms. In a randomised, double-blind, placebo-controlled trial, healthcare professionals (mainly nursing staff aged 18–65
years) from a university hospital in Berlin, Germany, were randomised to four capsules of dietary supplement (Juice Plus þ
w) or matching
placebo daily for 8 months, including a 2-month run-in period. The number of days with moderate or severe common cold symptoms
within 6 months (primary outcome) was assessed by diary self-reports. We determined means and 95% CI, and differences between
the two groups were analysed by ANOVA. A total of 529 subjects were included into the primary analysis (Juice Plus þ
w: 263, placebo:
266). The mean age of the participants was 39·9 (SD 10·3) years, and 80% of the participants were female. The mean number of days with
moderate or severe common cold symptoms was 7·6 (95% CI 6·5, 8·8) in the Juice Plus þ
w group and 9·5 (8·4, 10·6) in the placebo group
(P¼0·023). The mean number of total days with any common cold symptoms was similar in the Juice Plus þ
w and in the placebo groups
(29·4 (25·8, 33·0) v. 30·7 (27·1, 34·3), P¼0·616). Intake of a dietary supplement from fruits and vegetables was associated with a 20%
reduction of moderate or severe common cold symptom days in healthcare professionals particularly exposed to patient contact.
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The common cold is the most frequent acute illness in
industrialised societies. It is a viral infectious disease of
the upper respiratory tract, caused by a variety of viruses,
with rhinoviruses and corona viruses as the most
common. The leading symptoms include sneezing, runny
or congested nose, sore throat, headache and coughing,
typically lasting for about 5–10d. On average, adults
experience two to four colds per year
(1). Prevalence of
the common cold is clearly associated with the seasons.
In the Northern hemisphere, the frequency of common
cold infections increases in autumn and winter and
decreases in spring
(1).
The course of the common cold is usually benign;
however, it is a leading cause of absence from work and
doctor visits, responsible for a marked economic burden
including lost productivity and treatment costs. In the
USA, the common cold is estimated to cause twenty-three
million days of absence from work and cost $2 billion for
over-the-counter medication
(2).
Since there is no causal treatment for the common cold,
therapy focuses on symptom relief. In addition, preventive
strategies for the common cold include lifestyle measures
such as avoiding infected people and regular hand wash-
ing during the winter
(3). Dietary supplements including
herbs and vitamins have been suggested in the prevention
of the common cold, but previous investigations including
studies with Echinacea, an herbal supplement, found
supplements to be not effective for the prevention of
the common cold
(4), or yielded inconsistent results
(several studies on the effect of vitamin C). A randomised
controlled trial from Japan found a signiﬁcant reduction
of common cold episodes over a period of 5 years in
participants with high-dose v. low-dose vitamin C intake,
but no reduction in the duration or severity of the
common cold
(5). A recently published Cochrane review
has found no effect of vitamin C intake compared to
placebo for the incidence of the common cold (with the
exception of participants exposed to severe physical
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nstress or very cold environments), while an overall
reduction of 8% in common cold duration was reported
(6).
Juice Plus þ
w (NSA, Collierville, TN, USA) is a dietary
supplement composed primarily of juice powder concen-
trate from fruits and vegetables. It contains several anti-
oxidants including vitamin C, vitamin E, b-carotene and
folate, and it has been shown to increase plasma levels
of antioxidants and folate and of gd T cells, which are
believed to strengthen immune function
(7). One random-
ised study reported reduction in work days lost due to
illness in the Juice Plus þ
w group compared to the
placebo group
(8); however, the clinical beneﬁt for prevent-
ing or reducing common cold symptoms over the winter
season has not yet been tested in a large adult population.
Therefore, the aim of the present study was to determine
the effect of Juice Plus þ
w on the severity and frequency
of common cold symptoms in a population considered at
particular exposure.
Methods and materials
Study design and patients
In a randomised, double-blind, placebo-controlled trial,
volunteer participants were eligible for enrolment if they
met all of the following inclusion criteria: 18–65 years of
age; able and willing to take the active or placebo capsules
over the entire study period; healthcare professionals with
direct patient contact (physicians, nurses, physiotherapists,
etc.); written informed consent. Exclusion criteria were
acute inﬂuenza or common cold present at the time of
enrolment; known or suspected hypersensitivity or allergy
to one of the ingredients of Juice Plus þ
w; any alarming
symptoms such as signiﬁcant unintentional weight loss,
fever, or any other sign indicating serious or chronic
disease including suspected or conﬁrmed malignancy, or
other signiﬁcant cardiovascular, gastrointestinal, pulmon-
ary, renal, pancreatic or liver disease; alcohol addiction
or drug abuse; pregnancy or lactation; language limitations
regarding interviews and questionnaires.
The subjects were recruited by advertisements on
bulletin boards and the intranet in the Charite ´ University
Medical Center in Berlin, Germany, and screened by study
staff. The period of enrolment was from 12 September 2008
to 2 October 2008.
The subjects were allocated to the Juice Plus þ
w group
or the placebo group by computerised simple randomis-
ation. The dietary supplement and the matching placebo
were provided by the study sponsor and packaged in iden-
tical white bottles. Subjects were required to take four
study capsules daily including two capsules in the morning
with breakfast and two capsules in the evening with dinner
over a period of 8 months.
Baseline characteristics of subjects were assessed after
screening and inclusion in the study by questionnaire.
Common cold symptoms were documented by participants
with a validated common cold diary during the entire study
period
(9). The diary includes the following four symptom
categories: cough, nasal symptoms, throat symptoms
and general symptoms (fever, headache and aches), each
with a possible severity of none, light, moderate or severe.
The primary outcome was the number of days with at
least moderate (i.e. moderate or severe) common cold
symptoms within 6 months after an 8-week run-in
phase calculated from the common cold diary. Secondary
545 screened for eligibility
Two excluded (food allergy)
543 randomised
272 assigned to Juice Plus+
Nine withdrawn
Five lost to follow-up
Three health reasons
One chronic respiratory disease
263 valid for primary analysis 266 valid for primary analysis
271 assigned to placebo
Five withdrawn
Two lost to follow-up
One health reasons
One intake of other vitamins
One chronic respiratory disease
Fig. 1. Trial participant ﬂow.
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cold symptoms, common cold-related days unable to work,
days with common cold-related medication use and health-
related quality of life (SF-12). Compliance was assessed
by pill count from returned bottles by study staff and
calculated as proportion of capsules taken.
The present study was conducted according to the
guidelines laid down in the Declaration of Helsinki and
in accordance to International Conference on Harmonisa-
tion-Good Clinical Practice, and all procedures involving
human subjects were approved by the Institutional
Review Board (Charite ´ Ethics Committee). The study was
registered at ClinicalTrials.gov (NCT00778648). Written
informed consent was obtained from all the subjects.
Statistical analysis
A sample size of 235 in each group (470 in total) was esti-
mated to yield 90% power to detect a difference in means
of 3d of at least moderate common cold symptoms
(assumption in placebo group: mean of 20d; assumption
in Juice Plus þ
w group: mean of 17d) assuming a
common standard deviation of 10d and using a two-
sided t test with a signiﬁcance level of 0·05. Based on
this calculation and an assumed lost-to-follow-up rate of
10%, a total of 524 subjects were required for the study.
Descriptive analyses were done for all baseline variables,
and are given as means and standard deviations or
frequency with percentage according to the scale of the
variable. For the primary outcome, means and 95% CI
are reported, and the difference between study groups
was analysed using ANOVA with a signiﬁcance level of
0·05. Secondary outcomes were analysed likewise with
P values considered exploratory. All the analyses (includ-
ing randomisation) were done in SPSS 17.0 or Statistical
Analysis Systems 9.2 (SAS Institute, Cary, NC, USA).
Results
Of a total of 545 screened subjects, two subjects were
excluded because of food allergies. Thus, 543 subjects
were randomised, of those 271 subjects belong to the pla-
cebo group and 272 subjects belong to the Juice Plusþ
w
group. Twelve subjects (2·2%, four in placebo group and
eight in Juice Plus þ
w group) were withdrawn because
of dropout including lost to follow up or health reasons
during the run-in period without any data on common
cold symptoms, and two participants were withdrawn
due to chronic respiratory disease, one in the Juice
Plus þ
w group and one in the placebo group. Therefore,
the primary analysis groups included 263 subjects
randomised to Juice Plus þ
w group and 266 randomised
to placebo group (Fig. 1).
Most baseline characteristics of study participants were
similar between the two groups (Table 1). The majority
of the participants were females (77% in Juice Plus þ
w
group and 84% in placebo group). The mean age of the
study participants was 40·9 (SD 10·2) years in the Juice
Plus þ
w group and 38·8 (SD 10·3) years in the placebo
group. About one-third of the population were current
smokers. About 20% reported physical activity of less
than 1h/week, and 47 and 28% reported daily intake of
fruits and vegetables, respectively (Table 1). Inﬂuenza vac-
cination was obtained during the study period by 16% in
the Juice Plus þ
w group and 19% in the placebo group.
The mean number of days with at least moderate
common cold symptoms within 6 months after the run-in
period (primary outcome) was 7·6 (95% CI 6·5, 8·8)
in the Juice Plus þ
w group and 9·5 (95% CI 8·4, 10·6) in
the placebo group (P¼0·023). The mean number of days
with at least moderate common cold symptoms for the
entire study period (including run-in phase) in the control
Table 1. Baseline characteristics of study participants
(Number of participants and percentages)
Juice Plus þ
w
(n 263)
Placebo
(n 266)
n % n % P*
Age (years)† 40·9 10·2 38·8 10·3 0·016
Sex
Female 202 76·8 222 83·5 0·055
Male 61 23·2 44 16·5
BMI category (kg/m
2)
, 25 159 60·5 179 67·3 0·248
25– , 30 74 28·1 60 22·6
$ 30 30 11·4 27 10·2
Smoking status
Never 81 30·8 98 36·8 0·199
Ex 100 38·0 83 31·2
Current 82 31·2 85 32·0
Alcohol consumption
Never 36 13·7 33 12·4 0·496
Sometimes 206 78·3 204 76·7
Regular 21 8·0 29 10·9
Fruit consumption
Never or #1/week 30 11·4 31 11·7 0·831
2–3/week 55 20·9 64 24·1
4–6/week 50 19·0 50 18·8
Daily 128 48·7 121 45·5
Vegetable consumption
Never or #1/week 18 6·8 21 7·9 0·820
2–3/week 97 36·9 104 39·1
4–6/week 74 28·1 66 24·8
Daily 74 28·1 75 28·2
Physical activity
Never 12 4·6 13 4·9 0·662
, 1h/week 42 16·0 43 16·2
1 , 2·5h/week 81 30·8 94 35·3
$ 2·5h/week 128 48·7 116 43·6
Sauna visits
Never 187 71·1 182 68·4 0·217
1 per month 46 17·5 63 23·7
2–3 per month 16 6·1 10 3·8
Weekly 14 5·3 11 4·1
Quality of life†
SF-12 PCS 51·9 6·0 51·8 6·5 0·796
SF-12 MCS 52·3 6·9 51·4 7·6 0·150
PCS, physical component summary; MCS, mental component summary.
* P value from two-sample t test or x
2 test.
† Age and quality of life are given in terms of means and standard deviations.
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nand intervention group is given in Fig. 2, categorised with
respect to time period of occurrence. A disaggregation of
the primary outcome yielded 5·2 (95% CI 4·5, 6·0)d with
moderate symptoms in the Juice Plus þ
w group and 6·0
(95% CI 5·3, 6·8)d in the placebo group (P¼0·139), and
2·4 (95% CI 1·8, 3·0)d with severe symptoms in the Juice
Plus þ
w group and 3·5 (95% CI 2·9, 4·1)d in the placebo
group (P¼0·010). Adjusting the analysis of the primary
outcome for baseline characteristics (e.g. age and sex)
yielded results similar to the unadjusted results.
Both the groups were similar with regard to mean days
with any common cold symptoms within 6 months after
the run-in period (29·4 in Juice Plus þ
w group v.3 0 · 7i n
placebo group, P¼0·616; Table 2). Participants in the
Juice Plus þ
w group reported fewer days absent from
work during this period (2·5 v. 3·3d), but these differences
were not statistically signiﬁcant (P¼0·155). Participants in
the Juice Plus þ
w group reported fewer days with intake
of medication for common cold than participants in the
placebo group (5·7 v. 7·2d, P¼0·040; Table 2).
Health-related quality of life was similar in both the
groups at baseline (Table 1) and remained so during
the study period (data not shown) with no signiﬁcant
differences for all but one time point. At month 8, the
mean SF-12 physical component summary was 51·9 (95%
CI 51·1, 52·6) in the Juice Plus þ
w group and 51·5 (95%
CI 50·7, 52·4) in the placebo group (P¼0·566), while
the mental component summary was 53·7 (95% CI 52·8,
54·5) and 53·1 (95% CI 52·2, 53·9), respectively
(P¼0·313). Overall compliance was high in both the
groups with 96·0% in the Juice Plus þ
w group and
96·5% in the placebo group.
Discussion
Intake of a dietary supplement from fruits and vegetables
was associated with a 20% reduction in days of moderate
or severe common cold symptoms during the 6-month
study period. The number of days with any common
cold symptoms was not signiﬁcantly reduced. Thus, the
intervention appeared effective in the attenuation of symp-
tom level. This ﬁnding is corroborated by fewer days with
intake of common cold medication and a trend towards
fewer days absent from work due to the common cold in
the verum v. the placebo group.
The present study included an 8-week run-in phase,
because it was assumed that the intervention would not
be effective immediately. Indeed, no differences between
the two groups were observed within the ﬁrst 2 months
of the study, while later in the trial (months 3–6), a
reduction in the days with moderate or severe common
cold symptoms was found. It appears possible that an
earlier and longer run-in phase would have resulted in a
larger difference between the Juice Plus þ
w group and
the placebo group.
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Fig. 2. Number of days with at least moderate common cold symptoms for the entire study period including run-in period (months 1–2) and within 6 months after
the run-in period (months 3–8, primary outcome). Values we means, with 95% CI represented by vertical bars. B, Juice Plus þ
w; , placebo.
Table 2. Primary and secondary outcomes with respect to time
period of occurrence and within 6 months after 8-week run-in phase
(months 3–8)
(Mean values and 95% conﬁdence interval)
Juice Plus þ
w Placebo
Outcome Mean 95% CI Mean 95% CI P*
Days with at least moderate common cold symptoms
Months 1–2 3·4 2·8, 4·0 3·3 2·7, 3·9 0·909
Months 3–4 4·0 3·3, 4·7 4·7 4·0, 5·4 0·180
Months 5–6 2·1 1·6, 2·7 3·2 2·6, 3·8 0·014
Months 7–8 1·4 1·1, 1·8 1·6 1·2, 2·0 0·658
Months 3–8† 7·6 6·5, 8·8 9·5 8·4, 10·6 0·023
Days with any common cold symptoms
Months 1–2 12·6 11·2, 14·0 11·8 10·4, 13·2 0·440
Months 3–4 13·6 12·0, 15·1 13·7 12·2, 15·3 0·873
Months 5–6 9·3 7·8, 10·8 10·2 8·7, 11·7 0·387
Months 7–8 6·5 5·2, 7·8 6·8 5·5, 8·0 0·795
Months 3–8 29·4 25·8, 33·0 30·7 27·1, 34·3 0·616
Days absent from work due to common cold
Months 1–2 0·8 0·5, 1·1 0·8 0·6, 1·1 0·733
Months 3–4 1·3 0·9, 1·8 1·6 1·2, 2·1 0·392
Months 5–6 0·8 0·3, 1·2 1·2 0·7, 1·7 0·198
Months 7–8 0·4 0·2, 0·6 0·5 0·3, 0·8 0·504
Months 3–8 2·5 1·7, 3·3 3·3 2·5, 4·1 0·155
Days with intake of common cold medication
Months 1–2 2·6 2·0, 3·1 2·9 2·3, 3·4 0·476
Months 3–4 2·9 2·3, 3·6 3·7 3·0, 4·3 0·106
Months 5–6 1·6 1·1, 2·2 2·3 1·7, 2·8 0·093
Months 7–8 1·1 0·7, 1·4 1·3 0·9, 1·6 0·470
Months 3–8 5·7 4·6, 6·7 7·2 6·2, 8·3 0·040
*Pvalues from ANOVA.
† Primary outcome.
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fessionals and primarily nurses, a predominantly female
professional in Germany, the majority of participants
were female, limiting the generalisability of the results. In
addition, healthcare professionals may differ from the gen-
eral population regarding socio-economic variables or
health-related lifestyle. However, the reduction of days
with common cold symptoms was observed quite consist-
ently among several subgroups (e.g. participants with
higher or lower fruit or vegetable consumption).
The primary outcome was assessed by a common cold
diary, yielding a subjective measure of days with the
common cold. However, it would be difﬁcult to objectively
assess the number of days with the common cold in
a population consistently over several months. From a
patient’s perspective, the subjectively judged days with a
cold might be the outcome of choice, and due to the
double-blind design, the effect of the intervention should
not be biased.
Given the widespread utilisation of concentrated dietary
products, the present study has potentially important
public health relevance. To our knowledge, it is the ﬁrst
randomised investigation focusing on the beneﬁts of juice
powder concentrate in subjects particularly exposed to
patient contact. The conﬁrmation of the present ﬁndings
in other populations could contribute to the growing
scientiﬁc basis of assessing the clinical importance of
dietary supplements from fruits and vegetables.
In conclusion, intake of Juice Plus þ
w was associated
with fewer number of days with at least moderate
common cold symptoms. Whether long-term intake of
Juice Plus þ
w could further reduce severity or even the
frequency of common cold symptoms and the possible
underlying mechanisms should be assessed in future
studies.
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